BioAlliance gains US win for Sitavig single-use cold sore med
This article was originally published in Scrip
Executive Summary
The FDA has given patients with recurring Herpes labialis, better known as cold sores, something to smile about, with the approval of BioAlliance Pharma's Sitavig, a single-use prescription mucoadhesive tablet, which has been shown to reduce healing time and the severity of symptoms.